Effects of standardized extracts of St. John's wort on the single-unit activity of serotonergic dorsal raphe neurons in awake cats: Comparisons with fluoxetine and sertraline

Neuropsychopharmacology

Volumn 25, Issue 6, 2001, Pages 858-870

  Fornal, Casimir A ^a   Metzler, Christine W ^a   Mirescu, Christian ^a   Stein, Susan K ^a   Jacobs, Barry L ^a  

^a PRINCETON UNIVERSITY   (United States)

Author keywords

5 hydroxytryptamine (serotonin); Antidepressants; Dorsal raphe nucleus; Electrophysiology; Hypericum perforatum; LI 160; Selective serotonin reuptake inhibitors

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ANTIDEPRESSANT AGENT; AUTORECEPTOR; FLUOXETINE; HYPERICUM PERFORATUM EXTRACT; SEROTONIN; SEROTONIN 1A RECEPTOR; SERTRALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CAT; CELL ACTIVITY; CELL LEVEL; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; DRUG EFFECT; DRUG MECHANISM; MALE; NERVE CELL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; SEROTONINERGIC NERVE CELL; SINGLE UNIT ACTIVITY; SYNAPSE; WAKEFULNESS;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; CATS; ELECTROPHYSIOLOGY; FLUOXETINE; HYPERICUM; MALE; MEMBRANE POTENTIALS; NEURONS; PIPERAZINES; PLANT EXTRACTS; PYRIDINES; RAPHE NUCLEI; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; SERTRALINE;

EID: 0035673789     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00297-4     Document Type: Article

References (71)

1. Differential effects of clomipramine given locally or systemically on extracellular 5-HT in raphe nuclei and frontal cortex. An in vivo brain dialysis study
2. Specific systems of the reticular core: Serotonin
3. Physiology and pharmacology of central serotonergic neurons
4. 5-HT and antidepressants: New views from microdialysis studies
5. 1A antagonists
6. Drugs and the treatment of psychiatric disorders. Depression and mania
7. Venlafaxine: Discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites
8. Neuropharmacology of St. John's wort (Hypericum)
9. Activity profiles of two hyperforin-containing hypericum extracts in behavioral models
10. Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers
11. Inhibition of MAO by fractions and constituents of hypericum extract
12. Current advances and trends in the treatment of depression
13. A role for the serotonin system in the mechanism of action of antidepressant treatments: Preclinical evidence
14. Venlafaxine and its interaction with WAY 100635: Effects on serotonergic unit activity and behavior in cats
15. Hypericin and pseudohypericin: Pharmacokinetics and effects on photosensitivity in humans
16. St. John's wort set for U.S. clinical trials
17. Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity
18. Effects of Hypericum perforatum on levels of 5-hydroxytryptamine, noradrenaline and dopamine in the cortex, diencephalon and brainstem of the rat
19. The inhibitory effect of 8-OH-DPAT on the firing activity of dorsal raphe serotoninergic neurons in rats is attenuated by lesion of the frontal cortex
20. Hyperforin as a possible antidepressant component of hypericum extracts
21. Variations in hypericin concentrations in Hypericum perforatum L. and commercial products
22. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract
23. Effects of acute and chronic administration of fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat
24. Identification of selective MAO-type-A inhibitors in Hypericum perforatum L. (Hyperforat®)
25. 2 extract on dopamine and serotonin release in the rat central nervous system
26. Adverse effects profile of the herbal antidepressant St. John's wort (Hypericum perforatum L.)
27. Physiological and behavioral correlates of serotonergic single-unit activity
28. 1A antagonist, does not reverse the inhibition of serotonergic neuronal activity induced by fluoxetine in awake cats: Comparison to WAY-100635
29. 1A antagonist, increases serotonergic neuronal activity in behaving cats: Comparison with (S)-WAY-100135
30. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates
31. 1A autoreceptors and noradrenergic mechanisms
32. St John's wort for depression. A systematic review
33. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex
34. 1A receptor-induced inhibition of 5-HT neuronal activity in the rat
35. Effect of fluoxetine on extracellular 5-hydroxytryptamine in rat brain. Role of 5-HT autoreceptor
36. St John's wort (Hypericum perforatum) - A herbal antidepressant
37. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs)
38. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex
39. Structure and function of the brain serotonin system
40. Atlas of serotonergic cell bodies in the cat brainstem: An immunocytochemical analysis
41. Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity
42. St. John's wort: A new alternative for depression?
43. St. John's wort for depression. A meta-analysis of well-defined clinical trials
44. Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin
45. Antidepressant activity of Indian Hypericum perforatum Linn in rodents
46. Phytochemical characterization of various St. John's wort extracts
47. St. John's wort in mild to moderate depression: The relevance of hyperforin for the clinical efficacy
48. St John's wort for depression-an overview and meta-analysis of randomised clinical trials
49. Evaluation of major active components in St. John's wort dietary supplements by high-performance liquid chromatography with photodiode array detection and electrospray mass spectrometric confirmation
50. The serotonin hypothesis of major depression
51. Editorial
52. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity
53. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract
54. The experimental and clinical pharmacology of St John's wort (Hypericum perforatum L.)
55. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes
56. Pharmacological profile of hypericum extract. Effect on serotonin uptake by postsynaptic receptors
57. Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors
58. +1
59. 1A selective agonists
60. Comparison of the effects of sertraline and its metabolite desmethysertraline on blockade of central 5-HT reuptake in vivo
61. Hypericum for depression. An update of the clinical evidence
62. 14C]-labelled hypericin and pseudohypericin from Hypericum perforatum and serum kinetics of hypericin in man
63. Inhibition of MAO and COMT by hypericum extracts and hypericin
64. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
65. Hypericum perforatum extracts as potential antidepressants
66. Controlled clinical trials of hypericum extracts in depressed patients - An overview
67. Hypericum extract. Potential in the treatment of depression
68. Prozac (fluoxetine, Lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publication
69. 3H-GABA by hyperforin, a major constituent of St. John's wort. The role of amiloride sensitive sodium conductive pathways
70. Effect of the Hypericum perforatum extract on serotonin turnover in the mouse brain